GSK CEO Emma Walmsley will step down in 2025, with Luke Miels taking over as the company refocuses on pipeline growth and Montco operations.

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks. Read more here.

Stocks closed higher Monday, rebounding after a losing week, but the dollar and Treasury yields fell on fears of a possible ...

Luke Miels, GSK’s chief commercial officer, has been appointed CEO designate and will take over as chief executive on Jan. 1, 2026.

GSK's Emma Walmsley steps down, Luke Miels appointed CEO amid pipeline challenges. Kala Bio halts drug development causing ...

OpenAI is launching parental controls for ChatGPT, which it announced following a lawsuit alleging a teenager who died by ...

Dow Jones Top Company Headlines at 7 PM ET: YouTube to Pay $24.5 Million to Settle Lawsuit Brought by Trump | Vail ... The Google subsidiary is the final Big Tech company to resolve a trio of personal ...

In a series of notable announcements, GSK appoints insider Luke Miels as CEO while Emma Walmsley steps down. Kala Bio scraps ...

Wall Street ticked higher as technology stocks recovered some of their losses from last week. The S&P 500 added 0.3% Monday.

GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, the drugmaker said on ...

Nearly nine years ago, when Emma Walmsley was preparing to take over as CEO of GSK Plc, she wrote in her diary that Luke ...

GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the ...